The acquisition of Midazolam Nasal Spray (USL261) from Proximagen allowed UCB ( to pursue the consolidation of its epilepsy portfolio. The product is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive seizures (ARS) in patients with epilepsy, which has completed Phase 3 clinical development. USL2611 already granted orphan drug and fast track designation by the FDA and is ready to be filed as a New Drug Application (NDA) in the course of 2018.